Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
16 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Regenxbio (NASDAQ: RGNX ) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you APIs. For real-time access to our entire catalog, please visit for a consultation. View the webcast at Summary Regenxbio reported strong prog
UK regulator clears merger deal
Ford Motor Co. (NYSE: F ) shares are trading lower on Friday as investors weigh a mixed earnings follow-through and fresh analyst commentary on pricing and product mix. Ford Motor shares are under pressure. Why is F stock retreating? What Is Driving Ford’s Earnings Outlook? Ford’s latest update showed adjusted EPS of 4
Tempus AI Inc. (NASDAQ: TEM ) shares are trading lower on Friday as traders digest post-earnings reset in expectations. Tempus AI stock is trending lower. Why is TEM stock trading lower? What To Watch After Tempus AI’s Q2 Earnings Tempus reported second-quarter results after Thursday’s close, posting revenue of $382.5
AbbVie Inc. (NYSE: ABBV ) shares are retreating Friday as a modest reduction to full-year adjusted EPS guidance that pushed the midpoint beneath the analyst target proved enough to sour the market’s mood. Here’s what you should know. AbbVie shares are under pressure. Why are ABBV shares declining? A Guidance Trim Overs
Adj EPS $3.65 (est $3.61) - Net Rev. $16.99B (est $16.77B) - Skyrizi Rev $5.51B (est $5.43B) - RINVOQ Rev. $2.53B (est $2.48B) - Humira Rev $756M (est $734.1M) - Imbruvica $532M (est $563.2M) - Sees FY Adj EPS $13.87 To $14.07, Saw $13.91 To $14.11 - Yr View Incl Unfavourable Impact Of $0.58/SHR ON IPR&D - Yr View Incl
$ABBV AbbVie Q2 Earnings
ABBV AbbVie Inc RESULTS: Q2, Q2 global Skyrizi REV $5.505B, Q2 global Rinvoq REV $2.525B, Q2 global Humira REV $756M, Q2 ADJ EPS $3.65 vs. EST $3.60, Q2 REV $16.990B vs. EST $16.765B, Abbvie Inc Earnings Notes:, Q2 results include an unfavorable impact of $0.17/share related to acquired ipr&d and milestones expense, FY
Abbvie Q2 2026 Earnings
On Wednesday, Curis Inc. (NASDAQ: CRIS ) announced updated positive clinical trial results for its investigational drug emavusertib, alongside expanded trial timeline guidance. The biotechnology firm detailed key advances across its ongoing clinical programs evaluating the oral IRAK4 and FLT3 inhibitor for targeted blo
() -- Biopharma pricing power will be the key swing factor for Q2 earnings as companies with cleaner growth outlooks continue to outperform peers facing loss-of-exclusivity headwinds, Bank of America said in a note Friday. Merck & Co (MRK), AbbVie (ABBV), Jazz Pharmaceuticals (JAZZ) and Ionis Pharmaceuticals (IONS) rem
() -- AbbVie's (ABBV) Q2 financial results are expected to be in line with expectations, RBC Capital Markets analysts said in a Friday note. The company is scheduled to report its Q2 financial results on July 31. Analysts said sentiment on AbbVie has changed significantly, especially after the recent Apogee deal, which
Abbvie Q2 2026 Earnings
Guggenheim raised the firm's price target on AbbVie to $261 from $249 and keeps a Buy rating on the shares. The firm updated its model ahead of the Q2 earnings report.
In a regulatory filing, AbbVie said that reported GAAP earnings and adjusted non-GAAP earnings for the second quarter of 2026 are expected to include acquired IPR&D and milestones expense of $291 million on a pre-tax basis, representing an unfavorable impact of $0.17 to both GAAP diluted earnings per share and adjusted
* Sees Q2 Adj. Diluted EPS $3.57-$3.61 Including IPR&D Expense * Q2 Includes $291M Bought IPR&D Expense, Impacting GAAP And Adj. Diluted EPS By $0.17